Femasys
United States
9 articles about Femasys
-
Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada
5/3/2023
Femasys Inc. (NASDAQ: FEMY) today announced that Health Canada, the Public Health Agency of Canada, has granted product approval of FemCerv®, the first endocervical tissue sampler (curette) designed to collect and contain a comprehensive sample to maximize quality and quantity.
-
Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology
5/1/2023
Femasys Inc. (NASDAQ: FEMY) today announced that the Company’s management team will be attending the annual Conference for the American Society for Colposcopy and Cervical Pathology (ASCCP) held May 4 -7, 2023 at the Marriott Marquis in Houston.
-
Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada
4/18/2023
Femasys Inc. (NASDAQ: FEMY) today announced the Health Canada, the Public Health Agency of Canada, has granted product approval of FemaSeed®, the first-ever infertility solution designed to deliver sperm directly to where contraception occurs.
-
Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update
3/30/2023
Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the year ended December 31, 2022 and provided a corporate update.
-
Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023
3/9/2023
Femasys Inc. announced that Kathy Lee-Sepsick, founder, president & chief executive officer, will participate in the South By Southwest 2023 Conference being held in Austin, Texas from March 10-19, 2023.
-
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device
12/19/2022
Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that its product, FemCath™, the first FDA-cleared intrauterine catheter for selective tubal evaluation, is now commercially available.
-
Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons
12/12/2022
Femasys Inc. today reported that it held a promotional launch of its diagnostic product, FemCerv®, the first endocervical tissue sampler designed to improve tissue quality and quantity at the annual meeting of AAGL (formerly known as the meeting of the American Association for Gynecologic Laparoscopists), where the product was very well received by gynecologic physicians and surgeons.
-
Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design
11/29/2022
Femasys Inc. today announced that it has completed over 25% of its targeted enrollment (214 patient fertility cycles) in its FemaSeed ® de novo trial.
-
Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference
11/21/2022
Femasys Inc. today announced that the Kathy Lee-Sepsick, founder, president & chief executive officer, will present at the Piper Sandler 34th Annual Healthcare Conference being held November 29 through December 1, 2022 at the Lotte New York Palace.